Physician profile
Diego X Morillo
NPI 1811059785
$8,657.03
in general payments reported to CMS, 2019-2025
23 companies · $2,337 in 2025
The $2,337 reported for 2025 was more than what 97% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $413 · 2020: $383 · 2021: $718 · 2022: $1,667 · 2023: $1,025 · 2024: $2,115 · 2025: $2,337.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,477.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,477.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $1,663.94 | 2019-2025 | Cequa |
| Alcon Vision LLC | $979.57 | 2020-2025 | Tryptyr, Eysuvis, Precision7 |
| Tarsus Pharmaceuticals, INC. | $791.50 | 2024-2025 | Xdemvy |
| Biotissue Holdings INC. | $702.80 | 2024-2025 | |
| Sight Sciences, INC. | $611.21 | 2019-2022 | |
| Glaukos Corporation | $580.79 | 2021-2025 | Idose, Idosetr |
| Johnson & Johnson Vision Care, INC. | $549.73 | 2019-2024 | |
| Bausch & Lomb Americas INC. | $524.74 | 2023-2025 | Miebo, Xiidra, Vyzulta |
| Coopervision INC. | $520.96 | 2022-2024 | Misight Contact Lens, Myday Contact Lens |
| Oyster Point Pharma, INC. | $377.78 | 2022-2025 | Tyrvaya |
| Harrow Eye, LLC | $301.41 | 2024-2025 | Vevye |
| Allergan, INC. | $263.91 | 2019-2022 | |
| Dompe US, INC. | $161.26 | 2023-2025 | Oxervate |
| Rxsight INC | $147.03 | 2025 | Rxsight Light Delivery Device (Ldd), Rxsight Injector Handpiece, Rxsight Injector Cartridge |
| Novartis Pharmaceuticals Corporation | $140.80 | 2020-2023 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $115.87 | 2022 | |
| Samsara Vision | $62.50 | 2023 | |
| Kala Pharmaceuticals, INC. | $44.94 | 2021-2022 | |
| Lensar, INC. | $42.22 | 2025 | Lensar Laser System |
| Shire North American Group INC | $29.87 | 2019 | |
| Carl Zeiss Meditec, INC. | $17.24 | 2020 | |
| Eyevance Pharmaceuticals LLC | $15.79 | 2022 | |
| Optos, INC. | $11.17 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Diego Morillo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.